Literature DB >> 28350104

Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.

Ga Bin Park1, Yoon Hee Chung2, Daejin Kim3.   

Abstract

The expression of different toll-like receptors (TLRs) on tumor cells has been associated with disease aggressiveness, treatment resistance, and poor prognosis. The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is considered critical for cancer cell survival and proliferation. Thus, we investigated the effect of TLR-stimulated PI3K activation on the epithelial-to-mesenchymal transition (EMT) of primary (Caov-3) and metastatic (SK‑OV‑3) epithelial ovarian cancer cell lines in this study. TLR engagement with various ligands promoted the expression of class IA PI3K (p110α, p110β, and p110δ) and increased the expression of mesenchymal markers (N-cadherin, Slug, Vimentin, Snail, α-SMA, and TCF) in SK‑OV‑3 cells. The migratory activity and secretion of EMT-related cytokines of SK‑OV‑3 were significantly higher compared to those of Caov-3 after activation with TLR agonist. Although the invasive capacity and production of EMT-related cytokines of LPS-stimulated SK‑OV‑3 cells were significantly suppressed by all pharmacological inhibitors of the p110 isoform, the Syk/Src-dependent p110β isoform prominently attenuated migration activity. In contrast, the production of IL-10 and galectin-1 was mainly affected by the p110δ isoform. Gene silencing of TLR4 and galectin-1 with siRNA decreased the expression of matrix metalloproteinase-2 (MMP2) and MMP9 and reduced mesenchymal markers in LPS-treated SK‑OV‑3 cells. This study demonstrated that TLR-mediated PI3K activation modulated the invasion and metastasis of ovarian cancer through the production of galectin-1, suggesting that inhibition of the p110 isoform is a promising therapeutic approach against metastatic ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28350104     DOI: 10.3892/or.2017.5533

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  10 in total

1.  Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy.

Authors:  Qun Xu; Tian Li; Hekai Chen; Jun Kong; Liwei Zhang; Hang Yin
Journal:  RSC Med Chem       Date:  2021-09-07

Review 2.  IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.

Authors:  Ramesh B Batchu; Oksana V Gruzdyn; Bala K Kolli; Rajesh Dachepalli; Prem S Umar; Sameer K Rai; Namrata Singh; Pavan S Tavva; Donald W Weaver; Scott A Gruber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  CCDC106 promotes the proliferation and invasion of ovarian cancer cells by suppressing p21 transcription through a p53-independent pathway.

Authors:  Na Zhao; Chen Wang; Peng Guo; Jun Hou; Hong Yang; Ting Lan; Yehan Zhou; Jiayu Li; Ujjal K Bhawal; Yang Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

4.  TLR4 and MMP2 polymorphisms and their associations with cardiovascular risk factors in susceptibility to aortic aneurysmal diseases.

Authors:  Tan Li; Jingjing Jing; Liping Sun; Bo Jiang; Shijie Xin; Jun Yang; Yuan Yuan
Journal:  Biosci Rep       Date:  2019-01-08       Impact factor: 3.840

5.  Tumor-associated inflammatory microenvironment in non-small cell lung cancer: correlation with FGFR1 and TLR4 expression via PI3K/Akt pathway.

Authors:  Ruhui Zhang; Yongquan Dong; Mingjiao Sun; Yina Wang; Changqing Cai; Yun Zeng; Yueguang Wu; Qiong Zhao
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

Review 6.  The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling.

Authors:  Adrienn Sipos; Gyula Ujlaki; Edit Mikó; Eszter Maka; Judit Szabó; Karen Uray; Zoárd Krasznai; Péter Bai
Journal:  Mol Med       Date:  2021-04-01       Impact factor: 6.354

7.  Knockdown of circ_0067934 inhibits gastric cancer cell proliferation, migration and invasion via the miR‑1301‑3p/KIF23 axis.

Authors:  Jin Xu; Nan Sang; Junning Zhao; Wei He; Nannan Zhang; Xueliang Li
Journal:  Mol Med Rep       Date:  2022-04-27       Impact factor: 3.423

Review 8.  The Role of The Tumor Microbiome in Tumor Development and Its Treatment.

Authors:  Yan Chen; Fa-Hong Wu; Peng-Qiang Wu; Hong-Yun Xing; Tao Ma
Journal:  Front Immunol       Date:  2022-07-15       Impact factor: 8.786

9.  Heat Shock Proteins 70 Regulate Cell Motility and Invadopodia-Associated Proteins Expression in Oral Squamous Cell Carcinoma.

Authors:  Le-Xi Ding; Jing Zhang; Si-Si Yang; Jin Wu; Tong Su; Wei-Ming Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-26       Impact factor: 6.055

Review 10.  Galectins and Ovarian Cancer.

Authors:  Chisa Shimada; Rui Xu; Linah Al-Alem; Marina Stasenko; David R Spriggs; Bo R Rueda
Journal:  Cancers (Basel)       Date:  2020-05-31       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.